Gemini Therapeutics, Inc. (GMTX)
Gemini Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $1.35, up 0.00% on the session, giving a market capitalisation of $25.5M. Its beta of 0.00 implies it has historically moved less than the broad market.
Gemini Therapeutics, Inc. operates as a clinical-stage precision medicine enterprise, dedicated to crafting various therapeutic solutions for age-related macular degeneration (AMD) with a genetic foundation. Its flagship investigational product, GEM103, is a recombinant human complement factor H protein engineered to address dry AMD in patients. Beyond this, the firm is progressing GEM307, aimed at treating systemic ailments. Established in 2015, Gemini Therapeutics' operations are based out of Cambridge, Massachusetts.
Gemini Therapeutics, Inc. is most often compared with the following Healthcare names: